Calivanta BioPharma, a leading AI-powered precision medicine and drug discovery company, today announced the official opening of its new United States office, marking a significant milestone in the company’s global expansion strategy.
The new U.S. facility reinforces Calivanta’s commitment to serving its growing base of North American pharmaceutical and biotechnology partners. Located in a key U.S. biotech hub, the office will serve as the company’s primary center for FDA regulatory strategy, business development, and clinical collaboration across the Americas.
“Opening our dedicated U.S. office is a natural evolution of our mission to accelerate pharmaceutical innovation through data-driven discovery,” said a spokesperson for Calivanta BioPharma. “The United States represents the world’s largest pharmaceutical market and a critical center for regulatory excellence. Having boots on the ground here allows us to deepen our partnerships, streamline FDA engagement, and deliver faster value to our collaborators developing next-generation therapies.”
The expansion comes as Calivanta’s proprietary platforms — including CaliOmics for multi-omics target discovery, TherAlign for biomarker and companion diagnostic development, ImmunoScope for immuno-oncology analytics, PathwayPredict for systems pharmacology, and ClinicalConnect for real-world evidence integration — continue to gain traction with top-tier global pharmaceutical organizations and emerging biotech firms.
With operations now spanning three continents, Calivanta BioPharma is uniquely positioned to support partners through every stage of the drug development lifecycle, from target identification and validation through regulatory submission. The company’s SOC 2 Type II certified infrastructure, HIPAA-aligned data handling, and GDPR-compliant processing ensure enterprise-grade security for all partner collaborations.
The U.S. office will focus on three strategic priorities:
- Regulatory Strategy & FDA Liaison: Direct engagement with the U.S. Food and Drug Administration to support IND-enabling studies, companion diagnostic pathways, and regulatory submission strategies for partner programs.
- Business Development & Partner Success: Dedicated account management and scientific consulting for North American pharmaceutical companies, biotech startups, and academic medical centers.
- Clinical & Real-World Evidence Operations: Expansion of ClinicalConnect capabilities to leverage U.S. electronic health record and claims data for optimized trial design and portfolio prioritization.
Calivanta BioPharma currently maintains active partnerships with over 12 pharmaceutical organizations and supports ongoing development pipelines across oncology, immunology, and rare disease indications.
